{"id":"elbasvir-grazoprevir-oral-tablet-zepatier","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Asthenia"}]},"_chembl":{"chemblId":"CHEMBL3039533","moleculeType":"Small molecule","molecularWeight":"784.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Elbasvir is an NS5A inhibitor that prevents HCV protein complex formation and viral assembly. Grazoprevir is an NS3/4A serine protease inhibitor that blocks the cleavage of HCV polyproteins essential for viral replication. Together, they provide a potent combination therapy against HCV with high barrier to resistance.","oneSentence":"Elbasvir and grazoprevir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS5A and NS3/4A protease, respectively, blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:11.570Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6"},{"name":"Chronic hepatitis C virus infection, genotype 3 (with sofosbuvir)"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sofosbuvir/Ledipasvir","Sofosbuvir/Velpatasvir","Glecaprevir/Pibrentasvir","Sofosbuvir/Velpatasvir/Voxilaprevir"],"phase":"marketed","status":"active","brandName":"Elbasvir / Grazoprevir Oral Tablet [Zepatier]","genericName":"Elbasvir / Grazoprevir Oral Tablet [Zepatier]","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Elbasvir and grazoprevir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS5A and NS3/4A protease, respectively, blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6, Chronic hepatitis C virus infection, genotype 3 (with sofosbuvir).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}